- Home
- / Argenx
Argenx
Stock Price
$552.9
2024-10-29
Market Capitalization
$33.7 B
2024-10-29
Revenue
$4.2 B
FY, 2025
Argenx Summary
Company Summary
- Overview
- Argenx is a clinical-stage biotechnology company developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. It develops the Simple Antibody platform based on the llama immune system to develop antibody-based drugs.
- Type
- Public
- Status
- Active
- Founded
- 2008
- HQ
- Gent, BE | view all locations
- Website
- http://www.argenx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Tim van Hauwermeiren, Chief Executive Officer
Hans de Haard, Chief Scientific Officer
Dirk Beeusaert, General Counsel
LocationsView all
5 locations detected
Gent, Vlaams Gewest HQ
Belgium
Industriepark Zwijnaarde 7
Boston, MA
United States
33 Arch Street, 32nd floor Suite 3201
Minato City, Tokyo
Japan
2-5-8, Akasaka
Breda, NB
Netherlands
Willemstraat 5
Genève, GE
Switzerland
Rue du Pré-de-la-Bichette 1
Argenx Financials
Summary Financials
- Revenue (FY, 2025)
- $4.2B
- Gross profit (FY, 2025)
- $3.8B
- Net income (FY, 2025)
- $1.3B
- Cash (FY, 2025)
- $3.5B
- EBIT (FY, 2025)
- $1.0B
- Enterprise value
- $30.3B